Login / Signup

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.

Chantal MathieuGottfried RudofskyMoshe PhillipEiichi ArakiMarcus LindNiki AryaFredrik ThorénMarkus F ScheererNayyar IqbalParesh Dandona
Published in: Diabetes, obesity & metabolism (2020)
Dapagliflozin led to long-term reductions in HbA1c and body weight in adults with T1D, but increased DKA risk compared with placebo.
Keyphrases
  • body weight
  • type diabetes
  • glycemic control
  • placebo controlled
  • clinical trial
  • double blind
  • metabolic syndrome